Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival

References

• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.
   PubMed Web of Science ®Google Scholar
• Kim J-E, Kim Y-s, Rhim H, et al. Outcomes of patients with hepatocellular carcinoma referred for percutaneous radiofrequency ablation at a tertiary center: analysis focused on the feasibility with the use of ultrasonography guidance. Eur J Radiol. 2011;79:e80–e84.
   PubMed Web of Science ®Google Scholar
• Teratani T, Yoshida H, Shiina S, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006;43:1101–1108.
   PubMed Web of Science ®Google Scholar
• Reig M, Darnell A, Forner A, et al. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-Refined RECIST. Semin Liver Dis. 2014;34:444–455.
   PubMed Web of Science ®Google Scholar
• Vesselle G, Quirier-Leleu C, Velasco S, et al. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol. 2016;26:1640–1648.
   PubMed Web of Science ®Google Scholar
• Jung ES, Kim JH, Yoon EL, et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol. 2013;58:1181–1187.
   PubMed Web of Science ®Google Scholar
• Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012;56:1330–1335.
   PubMed Web of Science ®Google Scholar
• Terzi E, Golfieri R, Piscaglia F, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed on demand. J Hepatol. 2012;57:1258–1267.
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Mulcahy MF, Kulik LM, et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology. 2010;255:955–965.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, American A, for the S, of LD. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
   PubMed Web of Science ®Google Scholar
• Mgaieth S, Kemp W, Gow P, et al. Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: a large multicentre cohort study. J Viral Hepat. 2017;24:982–989.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver, European Organisation For Research and Treatment Of Cancer. EASL–EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos study. Hepatology. 1994;20:1442–1449.
   PubMed Web of Science ®Google Scholar
• Kirstein MM, Schweitzer N, Winter T, et al. Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma -experience from a referral center. J Gastro Hepatol. 2017;32:1730–1738.
   PubMed Web of Science ®Google Scholar
• Hocquelet A, Seror O, Blanc J-F, et al. Transarterial chemoembolization for early stage hepatocellular carcinoma decrease local tumor control and overall survival compared to radiofrequency ablation. Oncotarget. 2017;8:32190–32200.
   PubMedGoogle Scholar
• Kim HC, Suk KT, Kim DJ, et al. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. Wjg. 2014;20:745.
   PubMed Web of Science ®Google Scholar
• Guo Z, Zhong J-H, Jiang J-H, et al. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann Surg Oncol. 2014;21:3069–3076.
   PubMed Web of Science ®Google Scholar
• Yang H-J, Lee J-H, Lee DH, et al. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology. 2014;271:909–918.
   PubMed Web of Science ®Google Scholar
• Liem M-S-L, Poon R-T-P, Lo C-M, et al. Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. Wjg. 2005;11:4465–4471.
   PubMed Web of Science ®Google Scholar
• Chen R, Gan Y, Ge N, et al. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching. J Gastro Hepatol. 2016;31:442–449.
   PubMed Web of Science ®Google Scholar
• Kim JW, Kim JH, Sung K-B, et al. Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller. Am J Gastroenterol. 2014;109:1234–1240.
   PubMed Web of Science ®Google Scholar
• Hsu K-F, Chu C-H, Chan D-C, et al. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. Eur J Radiol. 2012;81:466–471.
   PubMed Web of Science ®Google Scholar
• Song YG, Shin SW, Cho SK, et al. Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients. Acta Radiol. 2015;56:70–77.
   PubMed Web of Science ®Google Scholar
• Bargellini I, Sacco R, Bozzi E, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol. 2012;81:1173–1178.
   PubMed Web of Science ®Google Scholar
• Sieghart W, Hucke F, Peck RM. Transarterial chemoembolisation: modalities, indication and patient selection. J Hepatol. 2015;62:1187–1195.
   PubMed Web of Science ®Google Scholar